The added value of pirfenidone to fight inflammation and fibrotic state induced by SARS-CoV-2

Abstract

Aim SARS-CoV-2 infection has been divided by scientific opinion into three phases: the first as asymptomatic or slightly symptomatic and the second and the third with greater severity, characterized by a hyperinflammatory and fibrotic state, responsible for lung lesions, in some cases fatal. The development of antiviral drugs directed against SARS-CoV-2 and effective vaccines is progressing; meanwhile, the best pharmacological objective is related to the management of all the complications caused by this viral infection, mainly controlling the inflammatory and fibrotic state and preventing the infection from moving into the most serious phases. Subject and method Describe the scientific rationale related to the use of an antifibrotic therapy with pirfenidone, as monotherapy and/or in combination with anti-inflammatory drugs to manage and control complications of SARS-CoV-2 infection. Results Based on the scientific literature and epidemiological results and considering the pathophysiological, biological, and molecular characteristics of SARS-CoV-2, an antifibrotic drug such as pirfenidone as monotherapy or in combination with antiinflammatory drugs can be (acting early, at the right doses and at the right time) therapeutically effective to avoid serious complications during viral infection. The same approach can also be effective as postinfection therapy in patients with residual pulmonary fibrotic damage. Management of inflammation and fibrotic status with a combination therapy of pirfenidone and IL-6 or IL-1 inhibitors could represent a pharmacological synergy with added value. Conclusion In this article, we consider the role of antifibrotic therapy with pirfenidone in patients with SARS-CoV-2 infection on going or in the stage of postinfection with pulmonary fibrotic consequences. The scientific rationale for its use is also described.

Efficacy of synthetic glucocorticoids in COVID-19 endothelites

“…SARS-CoV-2 uses the entry receptor ACE-2 to penetrate host cells (Li et al 2020a ; Vitiello and Ferrara 2020a , b ), the latter being expressed in several tissues, at the level of type II pneumocytes, cardiac cells, liver cholangiocytes, and endothelial cells. In the most severe stages of COVID-19 infection, a “cytokine cascade”(Vitiello et al 2020a ; Ferrara et al 2020a ) is generated, responsible for multi-system inflammation leading to organ injury (Ferrara et al 2020b ). As mentioned above, a percentage of COVID-19-infected patients show lesions of the cardiovascular system (Clerkin et al 2020 ; Vitiello and Ferrara 2020c ).…”

Correlation between the use of statins and COVID-19: what do we know?

“…Pulmonary fibrosis may be responsible for severe lung injury from COVID-19. 7 Some evidence associates pulmonary antifibrotic effects to statins. 8 Some studies have shown an increase in ACE-2 expression following treatment with statins.…”

Pharmacological approach for the reduction of inflammatory and prothrombotic hyperactive state in COVID-19 positive patients by acting on complement cascade

“…[ [1] , [2] , [3] , [4] , [5] , [6] , [7] , [8] , [9] , [10] , [11] , [12] , [13] , [14] , [15] , [16] , [17] , [18] , [19] , [20] , [21] , [22] , [23] , [24] , [25] , [26] , [27] , [28] , [29] , [30] , [31] , [32] , [33] , [34] , [35] , [36] , [37] , [38] , [39] , [40] , [41] , [42] , [43] , [44] , [45] , [46] , [47] , [48] , [49] , [50] , [51] , [52] , [53] , [54] ].…”